세계의 천식 치료제 시장 보고서 : 약제 클래스별, 제품 유형별, 치료 유형별, 투여 경로별, 지역별(2024-2032년)

The global asthma therapeutics market size reached US$ 18 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 22.0 Billion by 2032, exhibiting a growth rate (CAGR) of 1.9% during 2024-2032.

Asthma therapeutics refer to various pharmaceutical drugs that are used for the treatment of asthma. Asthma is usually triggered by indoor and outdoor causative agents, including pollution, allergens and dust. These therapeutics are usually bronchodilators and anti-inflammatory drugs, which include corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators and leukotriene modifiers. A number of combination therapy drugs are also used that can be inhaled, injected, or orally administered. These drugs expand the passageway into the lungs and enable the movement of air to improve breathing. They also aid in clearing mucus from the lungs that gets coughed out with ease.

Asthma Therapeutics Market Trends:

The increasing prevalence of asthma and other respiratory disorders, along with improvements in the diagnostic technologies, is one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the availability of effective asthma therapeutics is also providing driving the market growth. For instance, asthmatic patients are primarily treated with inhaled corticosteroids and patients with advanced conditions or persistent asthma are treated with target-specific drugs. There is also an extensive demand for monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines. The development of combination therapies for the treatment of respiratory diseases is acting as another growth-inducing factor. Increasing healthcare expenditures, extensive research, and development (R&D) activities in the field of medical sciences and improvements in the healthcare infrastructure are some of the other factors that are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global asthma therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug class, product type, treatment type and route of administration.

Breakup by Drug Class:

Anti-Inflammatory Drugs

Bronchodilators

Combination Therapies

Breakup by Product Type:

Inhalers

Dry Powder Inhalers

Metered Dose Inhalers

Soft Mist Inhalers

Nebulizers

Pneumatic Nebulizers

Ultrasonic Nebulizers

Mesh Nebulizers

Breakup by Treatment Type:

Quick-Relief Medications

Long-Term Asthma Control Medications

Breakup by Route of Administration:

Inhalation

Oral

Parenteral

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1. What was the size of the global asthma therapeutics market in 2023?
• 2. What is the expected growth rate of the global asthma therapeutics market during 2024-2032?
• 3. What are the key factors driving the global asthma therapeutics market?
• 4. What has been the impact of COVID-19 on the global asthma therapeutics market?
• 5. What is the breakup of the global asthma therapeutics market based on the drug class?
• 6. What is the breakup of the global asthma therapeutics market based on the product type?
• 7. What is the breakup of the global asthma therapeutics market based on the treatment type?
• 8. What is the breakup of the global asthma therapeutics market based on the route of administration?
• 9. What are the key regions in the global asthma therapeutics market?
• 10. Who are the key players/companies in the global asthma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Anti-Inflammatory Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Bronchodilators
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Combination Therapies
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Product Type

• 7.1 Inhalers
  • 7.1.1 Market Trends
  • 7.1.2 Major Types
    • 7.1.2.1 Dry Powder Inhalers
    • 7.1.2.2 Metered Dose Inhalers
    • 7.1.2.3 Soft Mist Inhalers
  • 7.1.3 Market Forecast
• 7.2 Nebulizers
  • 7.2.1 Market Trends
  • 7.2.2 Major Types
    • 7.2.2.1 Pneumatic Nebulizers
    • 7.2.2.2 Ultrasonic Nebulizers
    • 7.2.2.3 Mesh Nebulizers
  • 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

• 8.1 Quick-Relief Medications
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Long-Term Asthma Control Medications
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Inhalation
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Oral
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Parenteral
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 AstraZeneca PLC
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Abbott Laboratories
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Amgen Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Biogen Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Boehringer Ingelheim International GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 F. Hoffmann-La Roche Ltd.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 SWOT Analysis
  • 15.3.7 GlaxoSmithKline Plc
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Merck Sharp & Dohme Corp.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Novartis International AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Sunovion Pharmaceuticals Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 SWOT Analysis
  • 15.3.11 Teva Pharmaceutical Industries Ltd.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis